These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1552 related articles for article (PubMed ID: 25401325)
1. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325 [TBL] [Abstract][Full Text] [Related]
2. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70). Sugawara M; Goto Y; Yamazaki T; Teramoto T; Oikawa S; Shimada K; Uchiyama S; Ando K; Ishizuka N; Murata M; Yokoyama K; Uemura Y; Ikeda Y; Am J Cardiovasc Drugs; 2019 Jun; 19(3):299-311. PubMed ID: 30565155 [TBL] [Abstract][Full Text] [Related]
3. Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. Teramoto T; Shimada K; Uchiyama S; Sugawara M; Goto Y; Yamada N; Oikawa S; Ando K; Ishizuka N; Yamazaki T; Yokoyama K; Murata M; Ikeda Y Am Heart J; 2010 Mar; 159(3):361-369.e4. PubMed ID: 20211296 [TBL] [Abstract][Full Text] [Related]
4. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114 [TBL] [Abstract][Full Text] [Related]
5. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. Ogawa H; Nakayama M; Morimoto T; Uemura S; Kanauchi M; Doi N; Jinnouchi H; Sugiyama S; Saito Y; JAMA; 2008 Nov; 300(18):2134-41. PubMed ID: 18997198 [TBL] [Abstract][Full Text] [Related]
6. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. Matías-Guiu J; Ferro JM; Alvarez-Sabín J; Torres F; Jiménez MD; Lago A; Melo T; Stroke; 2003 Apr; 34(4):840-8. PubMed ID: 12649515 [TBL] [Abstract][Full Text] [Related]
7. Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project. Uchiyama S; Ishizuka N; Shimada K; Teramoto T; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Minematsu K; Matsumoto M; Ikeda Y; Stroke; 2016 Jun; 47(6):1605-11. PubMed ID: 27165949 [TBL] [Abstract][Full Text] [Related]
8. Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial. Benziger CP; Stebbins A; Wruck LM; Effron MB; Marquis-Gravel G; Farrehi PM; Girotra S; Gupta K; Kripalani S; Munoz D; Polonsky TS; Sharlow A; Whittle J; Harrington RA; Rothman RL; Hernandez AF; Jones WS JAMA Cardiol; 2024 Sep; 9(9):808-816. PubMed ID: 38985488 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of low-dose aspirin in polycythemia vera. Landolfi R; Marchioli R; Kutti J; Gisslinger H; Tognoni G; Patrono C; Barbui T; N Engl J Med; 2004 Jan; 350(2):114-24. PubMed ID: 14711910 [TBL] [Abstract][Full Text] [Related]
10. Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks. Ando K; Shimada K; Yamazaki T; Uchiyama S; Uemura Y; Ishizuka N; Teramoto T; Oikawa S; Sugawara M; Murata M; Yokoyama K; Ikeda Y; J Hypertens; 2019 Jun; 37(6):1301-1307. PubMed ID: 31022110 [TBL] [Abstract][Full Text] [Related]
11. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Bousser MG; Amarenco P; Chamorro A; Fisher M; Ford I; Fox K; Hennerici MG; Mattle HP; Rothwell PM; Cerebrovasc Dis; 2009; 27(5):509-18. PubMed ID: 19372653 [TBL] [Abstract][Full Text] [Related]
12. Low-dose aspirin for primary prevention of cardiovascular disease. Bredie SJ; Wollersheim H; Verheugt FW; Thien T Semin Vasc Med; 2003 May; 3(2):177-84. PubMed ID: 15199480 [TBL] [Abstract][Full Text] [Related]
13. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. Black HR; Elliott WJ; Grandits G; Grambsch P; Lucente T; White WB; Neaton JD; Grimm RH; Hansson L; Lacourciere Y; Muller J; Sleight P; Weber MA; Williams G; Wittes J; Zanchetti A; Anders RJ; JAMA; 2003 Apr 23-30; 289(16):2073-82. PubMed ID: 12709465 [TBL] [Abstract][Full Text] [Related]
14. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. Berger JS; Roncaglioni MC; Avanzini F; Pangrazzi I; Tognoni G; Brown DL JAMA; 2006 Jan; 295(3):306-13. PubMed ID: 16418466 [TBL] [Abstract][Full Text] [Related]
15. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Steinhubl SR; Bhatt DL; Brennan DM; Montalescot G; Hankey GJ; Eikelboom JW; Berger PB; Topol EJ; Ann Intern Med; 2009 Mar; 150(6):379-86. PubMed ID: 19293071 [TBL] [Abstract][Full Text] [Related]
16. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Gaziano JM; Brotons C; Coppolecchia R; Cricelli C; Darius H; Gorelick PB; Howard G; Pearson TA; Rothwell PM; Ruilope LM; Tendera M; Tognoni G; Lancet; 2018 Sep; 392(10152):1036-1046. PubMed ID: 30158069 [TBL] [Abstract][Full Text] [Related]
17. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. Lincoff AM; Tardif JC; Schwartz GG; Nicholls SJ; Rydén L; Neal B; Malmberg K; Wedel H; Buse JB; Henry RR; Weichert A; Cannata R; Svensson A; Volz D; Grobbee DE; JAMA; 2014 Apr; 311(15):1515-25. PubMed ID: 24682069 [TBL] [Abstract][Full Text] [Related]
18. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. Fowkes FG; Price JF; Stewart MC; Butcher I; Leng GC; Pell AC; Sandercock PA; Fox KA; Lowe GD; Murray GD; JAMA; 2010 Mar; 303(9):841-8. PubMed ID: 20197530 [TBL] [Abstract][Full Text] [Related]
19. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL; JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257 [TBL] [Abstract][Full Text] [Related]
20. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Bonaca MP; Goto S; Bhatt DL; Steg PG; Storey RF; Cohen M; Goodrich E; Mauri L; Ophuis TO; Ruda M; Špinar J; Seung KB; Hu D; Dalby AJ; Jensen E; Held P; Morrow DA; Braunwald E; Sabatine MS Circulation; 2016 Sep; 134(12):861-71. PubMed ID: 27576775 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]